SBIR/STTR Research Award

Prohealing Coatings for Cardiovascular Implants

Award identifier aa9858b9d83b116da9bfcd22f5ccf1c893baff4670a0dacff4d775c151709b92Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$297,258

Program and phase

SBIR · Phase I

Award year

2008

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
AFFINERGY, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
YJQ6K1QMS488
Solicitation number
PHS2007-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Summary Improving cardiovascular implants to reduce thrombosis and other confounds has been a long-term goal of medical science. Grafts and endovascular stents have been recently modified to include new materials, atta ched cells or drug-eluting polymers to make them more biocompatible. While these efforts represent substantial progress, the progression from inflammation to coagulation and eventual thrombosis still remains despite these interventions. Interference with t he health and continuity of the vascular endothelium is a challenging problem introduced by all cardiovascular implants. Any interruption of contact between terminally differentiated endothelial cells (ECs) and blood flow is likely to produce an undesirabl e prothrombotic response. Thus far, improved cardiovascular implants have employed materials such as expanded polytetrofluoroethylene (ePTFE), which provides a non-adherent surface and therefore inhibits coagulation. While an initial benefit, non-adherent surfaces also prevent endothelial cells from attaching to the endovascular surface, hampering the development of a protective endothelium. An unmet need therefore exists, to generate functionalized cardiovascular implants which encourage the development of endothelium on synthetic surfaces. Affinergy Inc. has developed bifunctional peptide linkers, called interfacial biomaterials (IFBMs) that help promote biology at the critical interface between a synthetic and a biologic. Attaching one peptide designed to bind endothelial cells; to another designed to bind a cardiovascular implant material would specifically encourage EC attachment to the endovascular surface. This approach is modular, allowing the guidance of multiple biological targets to various medical device materials. Here we propose the development of an IFBM to encourage the endothelialization of expanded PTFE grafts. Previously, we have observed encouraging in vivo results, using an IFBM for improved endothelialization of stainless steel stents. We are therefore eager to extend our work, and initiate the development of an EC: ePTFE IFBM. The overall goal of this project is to develop multifunctional adapter molecules that can mediate efficient recruitment, survival, and terminal differentiation of e ndothelial cells (ECs) on cardiovascular implants to promote their integration with the body. Efficient growth and coverage of ECs on ePTFE represents the proof of concept focus for this Phase I SBIR application. To accomplish the Aims proposed here, we wi ll first optimize ePTFE binding peptides and synthesize EC: ePTFE IFBMs. We will then verify IFBM stability and function in static biological fluids and under shear flow conditions. Second, building on the work we have done on stainless steel surfaces, we will evaluate EC migration and attachment on peptide coated ePTFE. Finally, we will evaluate the effect of IFBM-mediated cell attachment on EC phenotype. Project Narrative improving cardiovascular implants to reduce thrombosis and other confounds has been a long-term goal of medical science. Grafts and endovascular stents have been recently modified to include new materials, attached cells or drug-eluting polymers to make them more biocompatible. While these efforts represent substantial progress, the progr ession from inflammation to coagulation and eventual thrombosis still remains despite these interventions. Interference with the health and continuity of the vascular endothelium is a challenging confound introduced by all cardiovascular implants. Any inte rruption of contact between terminally differentiated endothelial cells (ECs) and blood flow is likely to produce an undesirable prothrombotic response. The overall goal of this project is to develop multifunctional adapter molecules that can mediate effic ient recruitment, survival, and terminal differentiation of endothelial cells (ECs) onto cardiovascular implants to promote their integration with the body.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

75 SBIR/STTR records share this UEI (2005–2023). Reported award amounts total $59,804,968. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.